- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05077072
Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients
Opioid-Sparing Interdisciplinary Interventions Addressing Pain in Head and Neck Cancer Patients
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. To test the hypothesis that this study will be feasible, as defined by adequate rates of adherence in the CHAT and NFB groups.
SECONDARY OBJECTIVES:
I. To examine the frequency of NMOU behaviors at the end of 3 months after CHAT, NFB, and SOC.
II. Examine the pain severity (area under the curve [AUC]), daily opioid use AUC of the cumulative morphine equivalent daily dose (MEDD), and mood (Hospital Anxiety and Depression Scale, HADS) for each of the treatment arms (CHAT, NFB, or SOC) in head and neck cancer (HNC) patients receiving radiation therapy at the end of 3 months.
EXPLORATORY OBJECTIVE:
I. To examine the cortical and subcortical regions of the brain associated with pain and our interventions (CHAT, NFB, and SOC) and the extent to which changes in electroencephalogram (EEG) patterns mediate the effects of the intervention.
OUTLINE: Patients are randomized into 1 of 3 arms.
ARM I: Patients participate in CHAT counseling intervention over 45-60 minutes twice a month for up to 12 weeks.
ARM II: Patients undergo NFB intervention over 20-30 minutes twice a week for up to 10 weeks.
ARM III: Patients receive 2-3 standard of care sessions per month over 45-60 minutes for up to 12 weeks.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Principal Investigator:
- Sriram Yennu
-
Contact:
- Sriram Yennu
- Phone Number: 713-792-6085
- Email: syennu@mdanderson.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of HNC, with patient scheduled to receive radiation therapy, with or without evidence of active disease
- Willingness to be seen in the outpatient supportive care center (SCC)
- History of use of non-medical opioid use (Screener and Opioid Assessment for Patients with Pain [SOAPP] >= 7+ and/or Cut Down, Annoyed, Guilty, and Eye opener questionnaire [CAGE] >= 2+)
- Physician-estimated prognosis of at least 12 months
- Age 18 or older
- Able to complete study assessments
- Willing to sign written informed consent
- Both human papillomavirus (HPV) and non-HPV patients will be included
- Patients currently receiving opioids for at least 1 week
- Able to read, write and speak English
Exclusion Criteria:
- Individual with clinically evident impaired cognition by Memorial Delirium Assessment Scale (MDAS) score of >= 13
- Employees of MD Anderson Cancer Center
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARM I (CHAT)
Patients participate in CHAT counseling intervention over 45-60 minutes twice a month for up to 12 weeks.
|
Ancillary studies
Participate in CHAT counseling intervention
Other Names:
|
Experimental: ARM II (NFB)
Patients undergo NFB intervention over 20-30 minutes twice a week for up to 10 weeks.
|
Ancillary studies
Undergo EEG
Other Names:
Undergo NFB intervention
Other Names:
|
Active Comparator: ARM III (SOC)
Patients receive 2-3 standard of care sessions per month over 45-60 minutes for up to 12 weeks.
|
Ancillary studies
Receive SOC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of non-medical opioid use (NMOU) behaviors
Time Frame: through study completion, an average of a year.
|
Composite NMOU score is calculated by summing the number of times each behavior suggestive of NMOU is recorded.
|
through study completion, an average of a year.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sriram Yennu, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-0337 (Other Identifier: M D Anderson Cancer Center)
- NCI-2021-09426 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Carcinoma
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Bristol-Myers SquibbActive, not recruitingSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
Ikena OncologyBristol-Myers SquibbWithdrawnHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head Cancer | Neck Cancer | Head Cancer Neck | Neck CarcinomaUnited States
-
Thompson Cancer Survival CenterRecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck CarcinomaUnited States
-
University of ChicagoRecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Head and Neck Cancer Stage IV | Head and Neck Cancers - ThroatUnited States
-
Washington University School of MedicineCelgene CorporationActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and NeckUnited States
-
University of AlbertaNot yet recruitingHead and Neck Cancer | Head and Neck Neoplasms | Head and Neck Squamous Cell Carcinoma | Head and Neck CarcinomaCanada
-
Kantonsspital Winterthur KSWUMC Utrecht; University of Lausanne; Zurich University of Applied Sciences; University... and other collaboratorsNot yet recruitingAdvanced Head and Neck Squamous Cell Carcinoma
-
University of California, DavisCompletedHead and Neck Cancer | Trauma | Head and Neck Squamous Cell Carcinoma | Head and Neck CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRegeneron PharmaceuticalsRecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | HNSCC | Head Cancer | Neck Cancer | Head Cancer NeckUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation
-
Karolinska University HospitalSahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Skane...Active, not recruitingQuality of Life | Vulvar CancerSweden